NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration
29 nov. 2023 08h30 HE
|
NurExone Biologic Inc
NurExone Biologic expands its portfolio of products to address spinal cord injuries & neuron regeneration in CNS indications
NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update
24 nov. 2023 08h30 HE
|
NurExone Biologic Inc
NurExone released a corporate update and reported financial results for the quarter ended September 30, 2023.
NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment
30 oct. 2023 09h20 HE
|
NurExone Biologic Inc
NurExone Biologic Receive FDA Orphan-Drug Designation to its ExoPTEN Therapy for Acute Spinal Cord Injury Treatment
Appointment of Professor Teo Forcht Dagi to Scientific Advisory Board and Advisory Committee
19 oct. 2023 08h30 HE
|
NurExone Biologic Inc
NurExone Biologic welcomes Prof. Teodoro Forcht Dagi, a renowned neurosurgeon and life science venture capitalist, to its Scientific Advisory Board.
ONWARD® kündigt die erste Implantation eines ARC-IM™-Stimulators mit Gehirn-Computer-Schnittstelle (BCI) beim Menschen an, um die Arm-, Hand- und Fingerfunktion nach einer Rückenmarksverletzung wiederherzustellen
27 sept. 2023 01h30 HE
|
ONWARD Medical NV
Eindhoven, Sept. 27, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), das Medizintechnikunternehmen, das innovative Therapien zur Rückenmarkstimulation entwickelt, um Bewegung,...
ONWARD® annonce la première implantation chez l'homme du stimulateur ARC-IM™ avec interface cerveau-ordinateur pour restaurer les fonctions du bras, de la main et du doigt après une lésion médullaire.
27 sept. 2023 01h30 HE
|
ONWARD Medical NV
Eindhoven, 27 sept. 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext : ONWD), l’entreprise de technologie médicale spécialisée dans la création de thérapies innovantes pour rétablir le...
ONWARD® kondigt aan dat ARC-IM™ stimulator met Brein-Computer Interface (BCI) voor het eerst bij mensen wordt geïmplanteerd om de functie van armen, handen en vingers na ruggenmergletsel te herstellen
27 sept. 2023 01h30 HE
|
ONWARD Medical NV
Eindhoven, Sept. 27, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), het medische technologiebedrijf dat innovatieve ruggenmergstimulatietherapieën ontwikkelt om beweging, functie en...
ONWARD® Announces First-in-Human Implant of ARC-IM™ Stimulator with Brain-Computer Interface (BCI) to Restore Arm, Hand, and Finger Function after Spinal Cord Injury
27 sept. 2023 01h30 HE
|
ONWARD Medical NV
Eindhoven, Sept. 27, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement,...
ONWARD® Startet Partnerschaft mit einem von Kriegsbehinderten geführten Unternehmen, um Zugang zum US-Bundesgesundheitsmarkt zu erhalten
13 sept. 2023 12h40 HE
|
ONWARD Medical
Eindhoven, Sept. 13, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), das Medizintechnikunternehmen, das innovative Therapien zur Wiederherstellung von Bewegung, Funktion und...
ONWARD® Launches Partnership with Service-Disabled Veteran-Owned Business to Access U.S. Federal Health Market
13 sept. 2023 12h40 HE
|
ONWARD Medical
Eindhoven, Sept. 13, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in...